Introduction
Apolipoprotein E (apoE) is a 32 kDa glycoprotein associated with the lipid transport and metabolism. The human APOE gene shows polymorphism, with the three different alleles, termed e2, e3, e4. 1 The protein is produced mainly in the liver. However, the second largest production of apoE is found in the brain, where it is mostly synthesized by astrocytes and microglia. 2, 3 ApoE has special relevance to the lipid metabolism in the nervous tissue. It plays a central role in modulating learning and memory, structural plasticity, mobilization of cholesterol in repair, growth and maintenance of myelin and neuronal membranes during development and aging, and cell death after ischemic, convulsive brain injury or other brain injury. [4] [5] [6] Since apoE is involved in the pathogenesis of neurodegenerative diseases, especially in Alzheimer's disease (AD). 7, 8 Numerous experimental studies have shown that apoE influences the majority of the AD pathological processes including amyloid-beta (Ab) deposition, tangle formation, oxidative stress, lipid homeostasis deregulation, synaptic plasticity loss and cholinergic dysfunction. 5, [9] [10] [11] In epilepsy, many studies are focus on APOE gene polymorphism. Gouras et al. 12 reported that APOE e4 allele promotes the intracerebral accumulation of b-amyloid in the patients with temporal lobe epilepsy (TLE); APOE e4 has also been found to be associated with earlier onset of TLE and cognitive impairment in TLE. 13, 14 In our previous study, we compared the cerebrospinal fluid (CSF) proteome of patients suffering from TLE and the control by polyacrylamide gel electrophoresis and found apoE expression had significant difference between TLE and control group. 15 We hypothesized that the role of apoE as an important factor in the response to seizure would be reflected by alterations in the concentration of apoE in the CSF. So we detected the apoE level in CSF of epileptic patients by enzyme-linked immunosorbent assay (ELISA).
Materials and methods
was diagnosed and classified according to the criteria proposed by International League Against Epilepsy in 2001. 16 Some patients with first-episode seizure do not have taken any anti-epileptic drugs (AEDs), others have taken one or more AEDs, including valproic acid, carbamazepine, topiramate, lamotrigine, and levetiracetam. Table 1 summarized the clinical features as follows. The control group consisted of 28 subjects ranging from 18 to 50 years old (27.2 AE 8.2 years) with 15 men and 13 women with no evidence of psychiatry or neurological or cardiovascular diseases or any past history of seizures. All people recruited in the research were of Chinese origin. The study was approved by the ethics committee of the First Affiliated Hospital of Chongqing Medical University, Chongqing, China. All epileptic patients and subjects had been given informed consent to participate in the study, which was performed in accordance with the Helsinki Declaration.
Samples collection and storage
2 ml CSF was collected from the cases and controls in sterile polypropylene tubes by lumbar puncture. 1 ml CSF samples sent to laboratory department of our hospital for total protein and biochemistry analysis, and 1 ml samples were centrifuged at 500 Â g (2000 rpm) for 10 min at 4 8C in refrigerated centrifuge (Sigma, USA) to separate cell component, and then CSF samples were divided into five parts in average and rapidly frozen and stored at À80 8C for later analysis.
Enzyme-linked immunosorbant assays
protecting from light. Add 50 ml stop solution to each well, if color change does not appear uniform. Finally, determine the optical density of each well at once, using a microplate reader set to 450 nm on Multiscan Spectrum Microplate Spectrophotometer (Thermo Fisher Scientific, USA).
Statistical analysis
Descriptive data were computed using means AE standard deviation (S.D.). The analysis was carried out using independent sample t-test and one-way analysis of variance (ANOVA). In the study, p value < 0.05 was considered significant. Statistical analysis was done using SPSS statistics 10.0.
Results
In our study, the age of epileptic patients at seizure onset was from 1 to 51 years old, and the mean age was 17.8 years old. The duration of disease was between 0 and 35 years, and mean duration was 10.4 years. 16.7% patients were suffered from firstepisode seizure, 25% patients had not so many as a 5 years history of seizures, and 68.3% had a clinical history of more than 5 years; 20% patients did not have taken any AEDs and 80% patients had taken one or more kinds of AEDs; 73.3% patients were idiopathic epilepsy, while 26.7% were secondary epilepsy, including secondary to trauma and encephalitis; In terms of seizure types, 30% patients were complex partial seizure (CPS), 35% were secondarily generalized tonic-clonic seizure (SGTC), 25% were generalized tonic-clonic seizure (GTCS), and 10% were absence seizure (AS). EP, epilepsy. * p < 0.05. Fig. 1 . The concentration of CSF-apoE in male and female patients (A), in idiopathic epilepsy and secondary epilepsy group (B), and in different seizure types groups (C). p < 0.05. Table 2 summarized the demographic characteristics of the subjects that participated in this study. There were no significant differences in age or sex of subjects between epilepsy and control group. CSF-apoE concentration in epilepsy group was 5.78 AE 2.15 mg/l, and was approximately two-fold lower than that of controls (13.60 AE 12.11 mg/l), and this difference was statistically significant (p < 0.05). The concentration of total protein in tow groups was similar (Table 3) . In epilepsy group, the concentrations of CSF-apoE were 6.53 AE 2.55 mg/l in male patients and 4.98 AE 1.21 mg/l in female, and there were statistical difference (p < 0.05) (Fig. 1A) . The mean levels of CSF-apoE in patients whose seizure onset age before 10, 10-20, and after 20 years old, were 5.67 AE 2.25 mg/l, 5.59 AE 1.96 mg/l and 6.09 AE 2.31 mg/l, respectively (p < 0.05) (Fig. 2A) . In different duration of disease groups, including first-episode seizure group (5.98 AE 2.18 mg/l), 5 years group (5.68 AE 1.57 mg/l) and >5 years group (5.77 AE 2.39 mg/l), there were no statistical difference (Fig. 2B) . The concentrations of CSF-apoE were 5.97 AE 1.88 mg/l and 5.73 AE 2.22 mg/l in no AEDs taking group and AEDs taking group, there were no statistical difference (Fig. 2C) . CSF-apoE in secondary epilepsy group (5.06 AE 1.31 mg/l) was lower than that in idiopathic epilepsy (6.04 AE 2.34 mg/l) (p < 0.05) (Fig. 1B) . In different seizure types groups, the mean concentrations of CSF-apoE were 6.62 AE 3.13 mg/l (CPS), 5.21 AE 1.22 mg/l (SGTC), 5.00 AE 1.09 mg/l (GTCS) and 7.25 AE 1.88 mg/l (AS), in SGTS and GTCS groups CSF-apoE levels were lower than that in CPS and AS groups (p < 0.05) (Fig. 1C) .
Discussion
The main finding of our study is that the concentration of CSFapoE of epileptic patients is substantially lower than non-seizure controls. This trend of CSF-apoE level is also detected in AD and traumatic brain injury.
A possible explanation for the decreased concentration of CSFapoE after seizure would be uptake by cells in contact with the CSF. Lipoprotein receptors are present in the ependymal cells lining the ventricular space, or astrocytes adjacent to the arachnoid space, and the cells of the arachnoid itself. 17, 18 Evidence from some studies supports the hypothesis that there is an increase in human and rats brain apoE after injury. In studies of brain tissue excision from patients undergoing surgery for medical intractable epilepsy, and postmortem material taking from Alzheimer's disease patient, strong apoE immunoreactivity was observed in many astrocytes and some cortical neurons. [19] [20] [21] Experimental seizure models induced by kainate identified increased apoE expression in hippocampus, this observation indicates that lipidic metabolism is modified in the lesioned structure and suggests an increased traffic of lipids and a need for more apoE in the hippocampus during the period of recovery and restructuration that follows severe seizures. 22 Thus CSF-apoE may be transported to the intracellular compartment and play an important role in the maintenance and repair of neurons. A further contributory factor diminishing the concentration of CSF-apoE after seizures might be decreased apoE synthesis in response to seizure. In vitro studies report reduced apoE levels in astrocyte culture medium in response to pro-inflammatory cytokines, which are known to be elevated after epileptic attack and other neurological disorders.
23-26
The concentration of CSF-apoE is correlated to gender. It may be related with estrogen, which has been shown to increase apoE levels in rat brain in vivo and in astrocytes and mixed glia cultures in vitro. 27, 28 In our study, we found the CSF-apoE levels had statistical difference between secondary epilepsy and idiopathic epilepsy. Seizures after traumatic brain injury and encephalitis are common secondary epilepsy, before epileptic attack, there have been neuronal necrosis. The concentration of apoE in CSF of patients with severe traumatic brain injury and subarachnoid hemorrhage is lower than controls and correlation with injury severity. 29, 30 We also found the CSF-apoE levels were correlated with the seizure types, when patients were suffering from SGTC and GTCS, their brain would be in hypoxia ischemia brain damage state. 31 The decrease of CSF-apoE after seizure might be related with the brain injury severity. Some studies detected a statistically significant result between an early age at onset of TLE and the presence of the APOE e4 allele. 13, 14 But our study did not find any association between CSFapoE and age of seizure onset. The concentration of CSF-apoE is not also related with duration of seizure and taking AEDs or not. These results suggest that CSF-apoE levels decreasing in epileptic patients might be a phenomenon responsing to seizures, not the reason causing epileptic attack.
In conclusion, decreased concentration of CSF-apoE in epileptic patients has been observed for the first time, and is correlated with the gender, etiological factor and seizure types. Further studies on the status of apoE levels in a larger number of epileptic patients with regularly follow-up would enable us to understand the possible role of apoE in epilepsy.
